Affiliated Institutions
Related Publications
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burd...
Seventy-Five Trials and Eleven Systematic Reviews a Day: How Will We Ever Keep Up?
When Archie Cochrane reproached the medical profession for not having critical summaries of all randomised controlled trials, about 14 reports of trials were being published per...
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
In patients with resectable NSCLC, neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathol...
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free ...
Extending the CONSORT Statement to Randomized Trials of Nonpharmacologic Treatment: Explanation and Elaboration
Adequate reporting of randomized, controlled trials (RCTs) is necessary to allow accurate critical appraisal of the validity and applicability of the results. The CONSORT (Conso...
Publication Info
- Year
- 2025
- Type
- article
- Citations
- 0
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
0
OpenAlex
Cite This
Hidetoshi Eguchi
(2025).
Is neoadjuvant therapy necessary for resectable pancreatic cancer? A review of randomized controlled trials to date: a narrative review.
International Journal of Clinical Oncology
.
https://doi.org/10.1007/s10147-025-02923-x
Identifiers
- DOI
- 10.1007/s10147-025-02923-x